Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Hepatitis B Clinical Trial

Official title:

A Phase 2, Open-label Study Evaluating the Intra-hepatic Effect of Inarigivir 400 mg Per Day and 400 mg Three Times Per Week on Immune Response and Viral Markers in Virally Suppressed Patients With Chronic Hepatitis B Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03932513
• Other study ID #: SBP-9200-HBV-203
• Status: Terminated
• Phase: Phase 2
• Start date: April 11, 2019
• Est. completion date: December 21, 2019

Study information

• Verified date: April 2020
• Source: Spring Bank Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

Description:

This is a single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: December 21, 2019
• Est. primary completion date: December 21, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male or female, aged = 21 to = 70 years

2. Chronic hepatitis B infection defined as HBsAg positive and on NUC therapy for at least one year.

1. Have at least one prior documented result of HBV DNA = 20 IU/mL LLOQ from a local laboratory, 6 or more months prior to Screening

2. HBV DNA = 20 IU/mL at Screening tested by the Central Laboratory

3. Have been on a commercially available HBV oral antiviral (OAV) treatment(s) (tenofovir alafenamide, tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, telbivudine, either as single agents or in combination) with no change in regimen for 3 months prior to screening.

3. Ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI) within 3 months of randomization date with no evidence of hepatocellular carcinoma

4. Must be willing and able to comply with all study requirements including two liver biopsies

5. Negative urine or serum pregnancy test (for women of childbearing potential documented within the 24-hour period prior to the first dose of test drug. If the urine pregnancy test is positive, a follow-up serum test is required for confirmation. Additionally, all fertile males with partners of childbearing age and females must be using reliable contraception during the study and for 3 months after treatment completion. All fertile males must also refrain from sperm donation while on Active drug and for 3 months after completion of Active drug.

6. Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures

Exclusion Criteria:

1. Any liver biopsy evidence of metavir F3 or F4 disease on any prior biopsy

2. Any history of decompensation of liver disease including history of ascites, encephalopathy, or varices

3. Evidence of advanced fibrosis at screening as defined by Fibroscan at the Screening Visit of = 8 kilopascals

4. Laboratory parameters not within defined thresholds: ALT or AST = 40 IU, white blood cells < 4500 cells/µL (SI unit < 4.5 × 109/L), hemoglobin (HgB) < 12 g/dL (SI unit < 120 g/L) for females, < 13 g/dL (SI unit < 130 g/L) for males, platelets < 150,000 per µL (SI unit < 150 × 109/L), albumin < 3.5 g/dL (SI unit < 35 g/L), international normalized ratio (INR) > 1.5, total bilirubin > 1.2 mg/dL (SI unit > 20.52 µmol/L), or alpha-fetoprotein (AFP) > 50 ng/mL (SI unit > 180.25 nmol/L). Patients with an elevated indirect bilirubin and known Gilbert's disease can be included if direct bilirubin is within normal limits. Patients with an AFP > 50 ng/mL but ? 500 ng/mL can be included if computed tomography (CT) scan or magnetic resonance imaging (MRI) performed within 3 months shows no evidence of hepatocellular carcinoma.

5. Creatinine > 1.2 mg/dL (SI unit > 106.08 µmol/L), creatinine clearance < 50 mL/min (SI unit < 0.83 L/s/m2)

6. Co-infection with hepatitis C virus, human immunodeficiency virus, or hepatitis D virus

7. Evidence or history of hepatocellular carcinoma

8. Malignancy within 5 years prior to Screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc.). Patients under evaluation for possible malignancy are not eligible.

9. Significant cardiovascular, pulmonary, or neurological disease

10. Received solid organ or bone marrow transplant

11. Received within 3 months of Screening or expected to receive prolonged therapy with immunomodulators (e.g., corticosteroids) or biologics (e.g., monoclonal antibody, Interferon)

12. Patients currently taking medication(s) that are transported through organic anion transporting polypeptide 1 including, but not limited to, atazanavir, rifampin, cyclosporine, eltrombopag, gemfibrozil, lopinavir/ritonavir, and saquinavir

13. Use of any herbal medications or supplements during the study period

14. Use of another investigational agent within 3 months of Screening

15. Current alcohol or substance abuse judged by the Investigator to potentially interfere with compliance

16. Females who are pregnant or may wish to become pregnant during the study

17. If the Investigator believes the prospective patient will not be able to comply with the requirements of the protocol and complete the study

18. Any medical condition, in the opinion of the Investigator, that could interfere with evaluation of the study objectives or safety of the patients

Related Conditions & MeSH terms

• HBV
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic

Intervention

Drug:
• inarigivir soproxil
Inarigivir 200mg and 400mg oral tablets, once daily

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
Spring Bank Pharmaceuticals, Inc.	CSI Medical Research Pte Ltd

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in intra-hepatic immune response	Relative change from Baseline to Week 6 of intra-hepatic immune response (quantitative measurement of 500-600 genes using Nanostring technology) in hepatocytes and liver immune cells derived from the central immunology core biopsy	6 Weeks
Primary	Change in intra-hepatic anti-viral response	Relative change from Baseline to Week 6 of intra-hepatic anti-viral response (HBV DNA, HBV RNA, HBV core levels, cccDNA and HBsAg levels) using PCR assays in hepatocytes and liver immune cells derived from the intra-hepatic virology biopsy.	6 Weeks
Secondary	Proportion of patients with an adverse event (AE), or a clinically significant clinical laboratory abnormality	Proportion of patients during the Baseline to Week 6 inarigivir treatment period with an adverse event (AE), or a clinically significant clinical laboratory abnormality	6 weeks
Secondary	Correlation of change of intra-hepatic immune markers, serum cytokines and PBMC activation	Correlation of change from Baseline to Week 6 of intra-hepatic immune markers, serum cytokines and PBMC activation measured by interferon-stimulated gene (ISG) production	6 weeks
Secondary	Correlation of change of intra-hepatic antiviral response and serum anti-viral response	Correlation of change from Baseline to Week 6 of intra-hepatic antiviral response and serum anti-viral response	6 weeks
Secondary	Comparison of change of intra-hepatic biomarkers of immune activation	Comparison of change in mRNA expression using Nanostring Technology, from Baseline to Week 6 of intra-hepatic biomarkers of immune activation between inarigivir 400 mg per day and 400 mg three times per week	6 weeks
Secondary	Comparison of change of peripheral biomarkers of immune activation	Comparison of change in mRNA expression using Nanostring Technology, from Baseline to Week 6 of intra-hepatic and peripheral biomarkers of immune activation and anti-viral response between inarigivir 400 mg per day and 400 mg three times per week	6 weeks
Secondary	Comparison of change of anti-viral response	Comparison of change in mRNA expression using Nanostring Technology, from Baseline to Week 6 of anti-viral response between inarigivir 400 mg per day and 400 mg three times per week	6 weeks
Secondary	Characterization of hepatic immune cells	Characterization by immuno-phenotyping of hepatic immune cells at Baseline and Week 6. Hepatic immune cells are analyzed and sorted by phenotype using markers of cell activation status through flow cytometry.	6 weeks
Secondary	Characterization of exhaustion markers	Characterization by immuno-phenotyping of exhaustion markers at Baseline and Week 6. Hepatic immune cells are analyzed and sorted by phenotype using markers T cell exhaustion through flow cytometry.	6 weeks